Healthcare Economics & Policy

A contract dispute between Chattanooga, Tennessee-based Erlanger Health System and Tennessee Interventional and Imaging Associates (TIAA) is threatening to upend the hospital’s premiere stroke program, according to documents obtained by the Times Free Press.

UnitedHealthcare partnered with Medtronic Feb. 1 to make the device company’s MiniMed 670G insulin pump system its preferred pump for diabetics aged 7 and up—a move the Juvenile Diabetes Research Foundation (JDRF) calls “an unacceptable step backward” and says effectively limits patients’ choices to one product.

ProvideGx, a subsidiary of Premier, will begin its offerings with metoprolol, a beta-blocker that can treat blood pressure and angina and is commonly given to heart attack patients.

Spending growth per Medicare beneficiary has slowed considerably since 2005, and 56 percent of that decline can be linked to reduced spending on cardiovascular disease and related risk factors, researchers reported Feb. 4 in Health Affairs.

Researchers predicted 12,400 additional deaths from cardiovascular disease (CVD) could occur in England between 2021 and 2030 if the United Kingdom severs preferential trading agreements with the European Union (EU) and prices of fruits and vegetables are impacted.

Johns Hopkins All Children’s Hospital in St. Petersburg, Florida, could lose its Medicare funding if it doesn’t shape up after a recent inspection found serious problems at the institution, The Tampa Bay Times reported.

General Electric (GE) has changed its original strategy and will now aim to sell nearly half of its healthcare unit, GE Healthcare, according to GE CEO Larry Culp.

Amid the FDA’s crackdown on the e-cigarette industry due to rising rates of teen vaping, a new randomized trial revealed e-cigs are effective for their original purpose: The devices were almost twice as successful as other nicotine replacement therapies, like patches and gums, in helping people stop smoking.

A health plan-wide intervention to switch diabetic patients from costly new insulin products to older, more affordable drugs resulted in a marginal increase in hemoglobin A1c (hbA1c) levels but didn’t change the rate of hospital visits for dangerously high or low blood sugar, researchers reported Jan. 29 in JAMA.

Direct oral anticoagulants (DOACs) are on their way to surpassing warfarin as the anticoagulant of choice among Medicaid beneficiaries, despite their higher cost, according to new research published in the Journal of the American College of Cardiology.

It isn’t too late to sustain a 50-year-long reduction in cardiovascular disease-related deaths, according to research published in Clinical Cardiology—but with rising rates of obesity and diabetes, we’re closer than ever to reversing that progress.

People taking the widely prescribed blood-pressure medication valsartan may have been exposed to a probable human carcinogen for at least four years after a change in the manufacturing process introduced the impurity, according to an update from the FDA’s ongoing investigation into the contaminants that have been found in a series of angiotensin II receptor blockers (ARBs).